Roche tests Parkinson's app, dismantles Heidelberg deal


Sign up online today & collaborate

or click here to find out more

Roche tests Parkinson's app, dismantles Heidelberg deal


Roche said earlier this week that its Pharma Research & Early Development unit has developed a smartphone-based monitoring system to measure the symptoms of Parkinson’s disease. 

The app is currently being used in a Phase I trial run by Prothena in collaboration with Roche, in what could be the first time such an app has been used to measure disease and symptom severity in a medicine development program in Parkinson’s disease, the firm noted.

Traditionally, disease disability and impairment are measured in trials by physician assessments using the Unified Parkinson’s Disease Rating Scale, but these are limited to the specific times. The app will enable continuous measurement of PD fluctuation every day and throughout the day. 

“Ultimately, we hope the app can be used in future clinical development to enable more objective measures on response to treatment to complement doctor assessments,” said Anirvan Ghosh, Head of Neuroscience Discovery for pRED

For more click here

Source: PharmaTimes

© Catalyst Innovation Portal 2019